Reporting by Ludwig Burger; editing by Matthias Williams
/cloudfront-us-east-2.images.arcpublishing.com/reuters/56X4QQ6MY5IHFCPDVCREVKJT2M.jpg)
The logo of BioNTech is pictured at Biontech’s research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/ File photo Acquire Licensing Rights
FRANKFURT, Nov 21 (Reuters) – COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna (MRNA.O) in litigation about alleged an patent violation by BioNTech and its partner Pfizer (PFE.N).
“We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1,” the German biotech firm said in a statement.
“The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted,” it added.
Reporting by Ludwig Burger; editing by Matthias Williams
Our Standards: The Thomson Reuters Trust Principles.
PARIS: France said on Wednesday that the European Union should consider sanctions on Israeli settlers who have targeted Palestinians in the West Bank as an opti
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/A752GPG7SJ3DD2BDJ632TFF5OM.jpg)
European shares rose on Wednesday, as German shares rallied. Better-than-expected inflation data in the euro zone’s largest economy boosted hopes that the Eur
/cloudfront-us-east-2.images.arcpublishing.com/reuters/V74RYRPTYBIZNBQWNLQZ5F3MQM.jpg)
A baggage belt truck passes behind the tail of a Scandinavian airline SAS Boeing 737 aircraft at the Stockholm-Arlanda airport in Sweden May 3, 2012. REUTERS/J
For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emailsSign up to our free breaking news emailsThe UK’s top sh
.jpeg?format=1500w)